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LETTER TO THE EDITOR
Response to article published in Vol. 3. No. 1.
Palliative response to radiotherapy in a patient with hypercalcemia
caused by metastatic adamantinoma
EDITOR Ð Lyons and colleagues report a patient
with metastatic adamantinoma complicated by hyper-
calcemia. We too have seen such a patient in whom
hypercalcemia was resistant to bisphosphonates but
initially responsive to chemotherapy.
In 1980 when aged 18 the patient underwent a
right above-knee amputation for adamantinoma of
the right tibia. In 1993 a thoracic vertebral metastasis
was excised, but recurred the following year. It was
again treated by debulking and radiotherapy, the
patient also undergoing removal of a single pulmonary
metastasis. In 1996 extensive liver and lung metas-
tases were noted.
At this time, serum calcium was noted to be
3.15 mmol/1 (normal range 2.2± 2.6 mmol/1).
Repeated infusions of pamidronate failed to improve
the hypercalcemia and he was therefore treated with
cisplatin 100 mg/m
2. There was normalisation of
the serum calcium within 3 weeks, but carboplatin
was subsequently substituted for cisplatin because
of renal dysfunction and severe tinnitus and hearing
loss.
There was no objective response in either the liver
or lung disease.
The patient remained normocalcaemic for 7 months
before the serum calcium rose again, to 4.02 mmol/1.
There was no response to either oral or intravenous
bisphosphonates or to the reintroduction of carbo-
platin. Oral corticosteroids were also unsuccessful and
the patient died of disease 5 months later.
Clearly this is a very uncommon complication of a
rare disease and indicates a poor prognosis. Lyons et
al., report of hypercalcemia resolving after radiation
to the hemithorax is interesting. In patients who may
have more widespread disease consideration should
be given to the use of platinum-based chemotherapy.
Yours sincerely
Dr Jeremy Whelan
Consultant Medical Oncologist
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